ProCE Banner Activity

CheckMate 8HW: Interim Analysis of Phase III Trial of Nivolumab + Ipilimumab vs Nivolumab for MSI-H or dMMR mCRC

Conference Coverage
Slideset

Interim analysis of CheckMate 8HW showed superior progression-free survival with nivolumab plus ipilimumab vs nivolumab monotherapy for MSI-H or dMMR metastatic colorectal cancer..

Released: February 04, 2025

Expiration: August 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation